Press Room

Press Clipping / Feb 25, 2021

Fire and evacuation drill at the pharmaceutical plant “Hovione”

News.Gov.MO, February 25, 2021

Fire and evacuation simulator at the pharmaceutical factory “Hovione” | Hovione

 
 

好利安藥廠火警疏散演習

Fire and evacuation simulator at the pharmaceutical factory “Hovione”

 

Firefighters fought the fire by the storage tank.

The Fire Brigade (CB) held on the morning of February 24th this year, a fire and evacuation simulator with dangerous chemical substances in the pharmaceutical factory “Hovione” together with Hovione FarmaCiencia SA, with the intention of intensifying the measures contingency and the coordination and communication mechanism between both parties in case of incidents.

The exercise simulated that a worker discovered that the leak occurred at the connection point of the methanol solution storage tank, thus causing a fire. The employee immediately sounded the fire alarm, the pharmaceutical factory's emergency and contingency team immediately proceeded to the internal contingency action, called the CB to ask for assistance and adopted security measures to evacuate the employees to the evacuation and meeting place. During the evacuation period, there was 1 worker who was injured. After becoming aware of the occurrence of a fire at the pharmaceutical factory “Hovione”, the CB immediately dispatched 9 emergency vehicles and 38 firefighters to the site to fight the fire, carry out the evacuation and search according to the defined plan, as well as provide nursing care for the injured and simulate transport to the hospital. The simulation lasted almost 1 hour.

CB and the pharmaceutical factory “Hovione” sent around 160 people to participate in the simulation, whose main purpose is to test the responsiveness and the communication mechanism between the relevant parties in case of incidents. The respective process went well, after the simulation, both parties held a review meeting, whose objectives and expected results were achieved.

[Translated from the original]

 

 
 

好利安藥廠火警疏散演習

為加強與好利安藥廠在發生事故時的應變措施及協調溝通機制，消防局於本年2月24日上午，與好利安製藥科學股份有限公司在氹仔好利安藥廠聯合舉行化學危險品火警及疏散演習。

演習模擬工作人員發現一個含有甲醇溶液的儲存缸接駁口出現洩漏並發生火警，工作人員隨即按動火警警報，藥廠緊急應變隊伍即時啟動內部應變計劃，同時致電消防局求助，以及採取安全措施疏散員工到逃生集合點，於疏散期間有一名員工不慎受傷。消防局接報好利安藥廠發生火警後，立即派遣9架緊急車輛及38名隊員趕赴現場，按照既定計劃進行滅火及疏散搜救行動，並對傷者進行即時護理及模擬送院，演習過程歷時約1小時。

消防局和好利安藥廠合共派出近160名人員參與是次演習，主要目的是測試發生事故時雙方的應變能力及溝通機制，演習過程順利，事後雙方進行檢討會議，並達到預期目的及效果。

 

 

Simulacro de incêndio e evacuação na fábrica farmacêutica “Hovione”

Os bombeiros combateram o fogo junto do tanque de armazenamento.

O Corpo de Bombeiros (CB) realizou na manhã do dia 24 de Fevereiro do corrente ano, um simulacro de incêndio e evacuação com substâncias químicas perigosas na fábrica farmacêutica “Hovione” em conjunto com a Hovione FarmaCiencia SA, com o intuito de intensificar as medidas de contingência e o mecanismo de coordenação e comunicação entre ambas as partes em caso de incidentes.

O exercício simulou que havia trabalhador que descobriu que ocorreu a fuga no ponto de ligação do tanque de armazenamento da solução de metanol, acontecendo assim um incêndio. O empregado tocou imediatamente o alarme de incêndio, a equipa de emergência e contingência da fábrica farmacêutica procedeu logo à acção de contingência interna, ligou ao CB para pedir auxílio e adoptou as medidas de segurança para evacuar os funcionários para o local de evacuação e encontro. Durante o período de evacuação, havia 1 trabalhador que ficou ferido. Depois de ter tido conhecimento da ocorrência de incêndio na fábrica farmacêutica “Hovione”, o CB enviou de imediato 9 veículos de emergência e 38 bombeiros ao local para combater o fogo, executar a acção de evacuação e busca conforme o plano definido, bem como prestar os cuidados de enfermagem junto do ferido e simular o transporte para o hospital. O simulacro durou quase 1 hora.

O CB e a fábrica farmacêutica “Hovione” enviaram cerca de 160 pessoas para participar no simulacro, cuja finalidade principal é testar a capacidade de resposta e o mecanismo de comunicação entre as partes pertinentes em caso de incidentes. O respectivo processo correu bem, depois do simulacro, ambas as partes procederam a uma reunião de revisão, cujos objectivos e resultados esperados foram alcançados.

 
Read the article at News.Gov.MO

 

 

 

 

Also in the Press Room

See All

The investment includes both continuous and batch tableting capabilities, as well as connect spray drying with tablet production at its East Windsor campus. Hovione, a Portugal-based contract development and manufacturing organization (CDMO), plans to install a continuous tableting line at its East Windsor, New Jersey campus, adding drug product manufacturing capacity and an integrated pathway from amorphous solid dispersion production through commercial tablet manufacturing. The $35 million investment will bring the first ConsiGma CDC Flex system to Hovione’s recently opened 89 Twin Rivers facility. The line is expected to be commissioned in late 2027 and will support both continuous and batch operation at throughputs ranging from 1 to 200 kilograms per hour, according to the announcement. The system will allow customers to use the same equipment for development, clinical, and commercial production, with formulation development possible using as little as 1.5 kilograms of material. Hovione said the line will also be equipped for containment to 1 microgram per cubic meter to support the handling of highly potent compounds. The new capability will also connect Hovione’s spray-drying operations with tablet manufacturing at the East Windsor campus. The company recently opened a 31,000-square-foot facility at the campus with two commercial-scale spray dryers for manufacturing amorphous solid dispersions (ASDs), completing a $100 million investment in its New Jersey operations. Hovione said the integrated setup will allow customers to move from formulation and particle engineering through tablet production under one quality system, reducing technology transfer requirements and eliminating traditional scale-up between development and commercial production. The ConsiGma CDC Flex platform was jointly developed with GEA as part of a collaboration that began in 2022, the company said. The system incorporates automated process controls and process analytical technology for real-time monitoring during production. Hovione already operates continuous tableting technology at its Loures, Portugal site. In August, the company completed a more than €40 million expansion of its tablet development and manufacturing center there, adding a second commercial-scale tableting line and increasing the center's manufacturing area by 25%. The East Windsor installation will extend Hovione’s continuous tableting capabilities to the U.S. and expand its integrated drug development and manufacturing services for oral solid dosage products. Read the full article at Pharma Manufacturing 

Press Clipping
Pharma Manufacturing, 6 October 2026

Hovione to add $35M continuous tableting line at New Jersey site

Oct 06, 2026

Hovione, a globally integrated pharmaceutical contract development and manufacturing organisation (CDMO), will commission the world’s first ConsiGma CDC flex – a next generation continuous tableting line – at its East Windsor, New Jersey (USA) campus in late 2027. The line will be installed at 89 Twin Rivers, Hovione’s recently opened facility, expanding the company’s drug product capabilities and strengthening its integrated pharmaceutical development and manufacturing hub in the US. CDC ConsiGma flex system The project represents an investment of $35 million. Once installed it will create an integrated pathway from amorphous solid dispersion manufacturing via spray drying through commercial tablet production. The new flex will operate in continuous or batch modes across a very broad throughput range (from one to 200 kg/h). Customers will be able to develop a formulation using small quantities of material, down to 1.5 kg, and then run from very small clinical batches to large commercial batches using the same equipment. This is enabled by specialised design within the flex to effectively switch between continuous blenders of various sizes. Additionally, the line will be installed for containment to 1 µg/m³, supporting highly potent compounds. Continuous tableting is reshaping manufacturing of oral solid dosage medicines and is well suited to programmes in which speed, supply resilience and efficient use of high-value active pharmaceutical ingredients (APIs) are priorities. Inline process analytical technology (PAT) and automated controls also provide real-time quality monitoring. In parallel, the 2022 adoption of ICH Q13 regulatory framework, guidance specifically for continuous manufacturing of drug substances and drug products, provides harmonisation across the US, Europe and Japan. As of 2024, 17 products manufactured under the international guidance have been approved by the US Food and Drug Administration (FDA) alone.  Developed jointly with GEA, the ConsiGma CDC flex platform also incorporates SimpleCT, a suite of automation and control tools with smart interfaces that supports a single process from development to commercial supply. Designed for versatility and ease of use, these innovative developments simplify operation, improve efficiency and containment, and enhance operator safety. Read the full article at Pharma Press UK 

Press Clipping
Pharma Press Global, 6 October 2026

Hovione to commission world’s first ConsiGma CDC flex, bringing next-generation continuous tableting to the US

Oct 06, 2026

Key Takeaways Commissioning a US-based ConsiGma CDC Flex line enables end-to-end spray drying-to-tablet manufacture within a single site and quality system, reducing comparability and technology-transfer burdens. Elimination of conventional scale-up is enabled by using the same equipment from early development through commercial supply, minimizing engineering runs and conserving scarce API. Operational flexibility spans batch or continuous modes and 1–200 kg/h throughput, with scale adjustment achieved by switching continuous blenders rather than replatforming processes. High-containment design to 1 µg/m³ expands suitability for highly potent oral solid-dose programs while maintaining integrated development-to-commercial workflows. Regulatory momentum for continuous manufacturing is supported by ICH Q13 harmonization, increasing FDA approvals, and platforms leveraging inline PAT and automated control suites for real-time quality assurance. Hovione announced on Oct. 5, 2026, that it will commission the ConsiGma CDC Flex, a next-generation continuous direct compression tableting platform jointly developed with GEA. The investment is designed to link amorphous solid dispersion manufacturing via spray drying with commercial tablet production at a single US site operating under one quality system. The line will run in either continuous or batch mode at throughputs from 1 to 200 kg/h. Formulation development can begin with as little as 1.5 kg of material, and the same equipment can then support everything from very small clinical batches to large commercial runs, enabled by a design that allows the system to switch between continuous blenders of different sizes. The installation will also be contained to 1 µg/m³ to accommodate highly potent compounds. "Hovione will be the first company in the world to offer the ConsiGma® CDC Flex, bringing this next-generation technology with unprecedented flexibility, simplicity and cost-efficiency in continuous tableting," said Marco Gil and António Almeida, co-CEOs, Hovione, said in a press release. "This investment also advances our strategy of building integrated capabilities close to customers in key markets. By adding this new line at East Windsor, we are broadening access to this technology in the U.S. and giving customers a more direct and accelerated path for developing and commercializing complex oral medicines." What Does a Single Development-To-Commercial Line Change? For formulators and process engineers, the most consequential claim is the removal of traditional scale-up. Moving a process from development equipment to commercial equipment typically requires engineering runs, bridging work, and consumption of scarce API, all of which weigh heavily on early programs with limited material. "Installing the CDC Flex at 89 Twin Rivers makes continuous tableting part of an integrated US development and manufacturing workflow," said David Basile, Vice President of Technical Operations, Hovione, in the press release. "Customers can move from formulation and particle engineering to commercial tablets with one Hovione team and one quality system, eliminating traditional scale-up while gaining greater production flexibility, process control and supply continuity." Co-locating spray drying and tableting is also significant because amorphous solid dispersions remain a primary solubility-enhancement route for poorly soluble molecules, and transferring intermediates between sites or vendors adds technology transfer and comparability burdens. The new line builds on the company's earlier US expansion; Hovione recently completed a $100 million investment to bolster US capacity in particle design, amorphous solid dispersions via spray drying, and batch and continuous tableting. How Is the Regulatory Environment Shaping Continuous Tableting Adoption? The company points to the 2022 adoption of ICH Q13, which provides harmonized guidance for continuous manufacturing of drug substances and drug products across the US, Europe, and Japan. Hovione reports that, as of 2024, FDA alone had approved 17 products manufactured under the guidance. Speaking on ICH Q13, FDA's Kelley Burridge, PhD, "Perceived barriers to continuous manufacturing have been falling one by one," and noted an FDA publication showing faster approval times for products with continuous manufacturing elements than for comparable batch products. The platform incorporates inline process analytical technology and automated controls for real-time quality monitoring, along with SimpleCT, an automation and control suite intended to support a single process from development through commercial supply. For sponsors weighing supply resilience and regional sourcing, the East Windsor installation extends a capability that Hovione says only it currently offers as a contract development and manufacturing organization.   Read the full article at PharmTech.com  

Press Clipping
PharmTech, 5 October 2026

Can Continuous Tableting End Scale-Up for Complex Oral Drugs?

Oct 05, 2026

Also in Events

See All